Icosavax Stock Fundamentals
| ICVXDelisted Stock | USD 9.02 0.12 1.31% |
Icosavax fundamentals help investors to digest information that contributes to Icosavax's financial success or failures. It also enables traders to predict the movement of Icosavax Stock. The fundamental analysis module provides a way to measure Icosavax's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Icosavax stock.
Icosavax |
Icosavax Company Current Valuation Analysis
Icosavax's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Icosavax Current Valuation | 547.9 M |
Most of Icosavax's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Icosavax is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Icosavax has a Current Valuation of 547.9 M. This is 96.19% lower than that of the Biotechnology sector and 88.21% lower than that of the Health Care industry. The current valuation for all United States stocks is 96.7% higher than that of the company.
Icosavax Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Icosavax's current stock value. Our valuation model uses many indicators to compare Icosavax value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Icosavax competition to find correlations between indicators driving Icosavax's intrinsic value. More Info.Icosavax is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Icosavax's earnings, one of the primary drivers of an investment's value.Icosavax Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Icosavax's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Icosavax could also be used in its relative valuation, which is a method of valuing Icosavax by comparing valuation metrics of similar companies.Icosavax is currently under evaluation in current valuation category among its peers.
Icosavax Fundamentals
| Return On Equity | -0.42 | |||
| Return On Asset | -0.27 | |||
| Current Valuation | 547.9 M | |||
| Shares Outstanding | 50.23 M | |||
| Shares Owned By Insiders | 3.47 % | |||
| Shares Owned By Institutions | 87.64 % | |||
| Number Of Shares Shorted | 321.31 K | |||
| Price To Earning | 63.56 X | |||
| Price To Book | 3.31 X | |||
| Price To Sales | 153.31 X | |||
| Gross Profit | (30.97 M) | |||
| EBITDA | (103.19 M) | |||
| Net Income | (96.71 M) | |||
| Cash And Equivalents | 242.8 M | |||
| Cash Per Share | 6.09 X | |||
| Total Debt | 8.79 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 20.89 X | |||
| Book Value Per Share | 4.64 X | |||
| Cash Flow From Operations | (71.48 M) | |||
| Short Ratio | 0.34 X | |||
| Earnings Per Share | (2.20) X | |||
| Target Price | 18.5 | |||
| Number Of Employees | 60 | |||
| Beta | 1.28 | |||
| Market Capitalization | 769.04 M | |||
| Total Asset | 238.68 M | |||
| Retained Earnings | (185.83 M) | |||
| Working Capital | 210.12 M | |||
| Z Score | 51.0 | |||
| Net Asset | 238.68 M |
About Icosavax Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Icosavax's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Icosavax using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Icosavax based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company was incorporated in 2017 and is headquartered in Seattle, Washington. Icosavax operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Icosavax Stock
If you are still planning to invest in Icosavax check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Icosavax's history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |